Ophthalmic steroid - ISTA Pharmaceuticals

Drug Profile

Ophthalmic steroid - ISTA Pharmaceuticals

Latest Information Update: 22 May 2014

Price : $50

At a glance

  • Originator ISTA Pharmaceuticals
  • Class Steroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Phase I Ocular inflammation

Most Recent Events

  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb
  • 31 Mar 2009 Phase-I clinical trials in Ocular inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top